Drug profile · INN
dipyridamole
DIPYRIDAMOLE
dipyridamole (DIPYRIDAMOLE) is a 3',5'-cyclic phosphodiesterase inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — dipyridamole
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 5
- Programs
- 4
- Data quality
- 0.84
Quick answer
dipyridamole (DIPYRIDAMOLE) is a 3',5'-cyclic phosphodiesterase inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
3',5'-cyclic phosphodiesterase inhibitor
Primary target: 3',5'-cyclic phosphodiesterase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 10973758
Methods of eye treatment using therapeutic compositions containing dipyridamole
granted -
US 10357453
Methods of eye treatment using therapeutic compositions containing dipyridamole
granted -
US 10322129
Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions and methods for producing same
granted -
US 10226420
Methods of eye treatment using therapeutic compositions containing dipyridamole
granted -
US 9901580
Methods of eye treatment using therapeutic compositions containing dipyridamole
granted
Frequently asked questions
What is dipyridamole?
dipyridamole (DIPYRIDAMOLE) is a 3',5'-cyclic phosphodiesterase inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for dipyridamole?
DIPYRIDAMOLE is a marketed brand name for dipyridamole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dipyridamole?
dipyridamole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.